Fructose in Exercising Individuals With Type 1 Diabetes Using Insulin Degludec
FruDeg
Fructose to Reduce Exercise-associated Hypoglycaemia in Individuals With Type 1 Diabetes Treated With Insulin Degludec: Questioning a Paradigm and Offering a Novel Strategy
1 other identifier
interventional
15
1 country
1
Brief Summary
To determine and compare the time-to-hypoglycaemia (defined as plasma glucose \<3.9mmol/L) in individuals with type 1 diabetes treated with ultra-Long acting insulin degludec during aerobic exercise with or without prior ingestion of a single oral fructose load.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 6, 2018
CompletedFirst Posted
Study publicly available on registry
April 13, 2018
CompletedStudy Start
First participant enrolled
January 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 6, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 8, 2019
CompletedSeptember 20, 2019
September 1, 2019
8 months
April 6, 2018
September 19, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l)
The development of hypoglycaemia will be determined by repeated measurement of plasma glucose.
From time point 0 minutes (initiation of exercise) to time point 60 minutes (completion of exercise) or development of hypoglycaemia
Secondary Outcomes (15)
Glucose levels before exercise
Time point -30 minutes until time point 0 minutes (initiation of exercise)
Glucose levels during exercise
From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia
Glucose levels after exercise
From time point 0 minutes until time point 90 minutes
Lactate levels before exercise
From time point -30 minutes until time point 0 minutes (initiation of exercise)
Lactate levels during exercise
From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia
- +10 more secondary outcomes
Study Arms (2)
Fructose in water first, water only second
EXPERIMENTALIntake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
Water only first, Fructose in water second
EXPERIMENTALIntake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
Interventions
Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
Eligibility Criteria
You may qualify if:
- Type 1 diabetes as defined by the World Health Organization (WHO) for at least 1 year or confirmed negative C-peptide (\<100pmol/l with concomitant blood glucose \>4 mmol/l)
- Male subjects aged between 18-45 years
- HbA1c \<8.0% (64mmol/mol) based on analysis from the central laboratory unit of the University Hospital Bern.
- Basal/Bolus-insulin regimen with insulin degludec for at least 3 months, with good knowledge of insulin self-management
- Regular physical activity (at least 30 min of moderate exercise 3 times weekly)
- Written informed consent
You may not qualify if:
- Relevant diabetic complications as judged by the investigator
- Total daily insulin dose \>2 IU/kg/day
- Hypoglycaemia unawareness (Gold score \> 4) or any episode of severe hypoglycaemia as defined by the American Diabetes Association within the last 6 months
- Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
- Current treatment with drugs known to interfere with metabolism, e.g. systemic corticosteroids, statins etc.
- Known fructose-intolerance or malabsorption
- Known allergy to one of the study drugs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
Bern, 3010, Switzerland
Related Publications (1)
Kosinski C, Herzig D, Laesser CI, Nakas CT, Melmer A, Vogt A, Vogt B, Laimer M, Bally L, Stettler C. A Single Load of Fructose Attenuates the Risk of Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes on Ultra-Long-Acting Basal Insulin: A Randomized, Open-Label, Crossover Proof-of-Principle Study. Diabetes Care. 2020 Sep;43(9):2010-2016. doi: 10.2337/dc19-2250. Epub 2020 Jun 26.
PMID: 32591421DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christoph Stettler, MD
Inselspital, Bern University Hospital, University of Bern
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 6, 2018
First Posted
April 13, 2018
Study Start
January 4, 2019
Primary Completion
September 6, 2019
Study Completion
September 8, 2019
Last Updated
September 20, 2019
Record last verified: 2019-09